Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EBITDA (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed EBITDA for 7 consecutive years, with -$976000.0 as the latest value for Q3 2025.

  • For Q3 2025, EBITDA fell 34.99% year-over-year to -$976000.0; the TTM value through Sep 2025 reached -$3.6 million, up 33.13%, while the annual FY2024 figure was -$3.6 million, 71.99% up from the prior year.
  • EBITDA hit -$976000.0 in Q3 2025 for Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $502000.0 in Q4 2024 and bottomed at -$16.2 million in Q2 2021.
  • Average EBITDA over 5 years is -$6.5 million, with a median of -$4.5 million recorded in 2022.
  • Year-over-year, EBITDA skyrocketed 127.97% in 2024 and then crashed 34.99% in 2025.
  • Cyclerion Therapeutics' EBITDA stood at -$14.3 million in 2021, then surged by 68.93% to -$4.5 million in 2022, then surged by 59.71% to -$1.8 million in 2023, then surged by 127.97% to $502000.0 in 2024, then plummeted by 294.42% to -$976000.0 in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$976000.0, -$1.7 million, and -$1.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.